ASTRAZENECA News & Analysis

Demand for covid-19 vaccines has seen interest in pharma stocks soar, but Morningstar analysts think this is a temporary trend.

The plasma giant remains overvalued, according to Morningstar.

Astra’s vaccine looks potentially easier to transport with only mild temperature requirements as compared with the other vaccines.

These stocks could benefit from the race to roll out antibody therapy for covid-19, writes Vikram Barhat.

We expect most US adults will be vaccinated in the first half of 2021, writes Morningstar healthcare strategist Karen Andersen.

Three new vaccines for coronavirus look poised for emergency use authorisation in the US this autumn. What does that mean for investors?